Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

NCT05433532 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Philadelphia Chromosome
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Mixed Phenotype Acute Leukemia

Interventions

DRUG: Azacitidine
DRUG: Venetoclax
DRUG: Flumatinib

Sponsor

The First Affiliated Hospital of Soochow University